Asymptomatic left circumflex artery stenosis is associated with higher arrhythmia recurrence after persistent atrial fibrillation ablation

Rodrigue Garcia, Mathilde Clouard, Fabian Plank, Bruno Degand, Séverine Philibert, Gabriel Laurent, Pierre Poupin, Saliman Sakhy, Matthieu Gras, Markus Stühlinger, et al.

To cite this version:

Rodrigue Garcia, Mathilde Clouard, Fabian Plank, Bruno Degand, Séverine Philibert, et al.. Asymptomatic left circumflex artery stenosis is associated with higher arrhythmia recurrence after persistent atrial fibrillation ablation. Frontiers in Cardiovascular Medicine, 2022, 9, pp.873135. 10.3389/fcvm.2022.873135. hal-04628693
Asymptomatic left circumflex artery stenosis is associated with higher arrhythmia recurrence after persistent atrial fibrillation ablation

Rodrigue Garcia1,2*, Mathilde Clouard1, Fabian Plank3, Bruno Degand4, Séverine Philibert4, Gabriel Laurent5, Pierre Poupin6, Saliman Sakhy5, Matthieu Gras1, Markus Stühlinger3, Nándor Szegedi7, Szilvia Herczeg7, Judit Simon7, Harry J. G. M. Crijns8, Eloi Marijon4, Luc Christiaens1 and Charles Guenancia5

1Cardiology Department, University Hospital of Poitiers, Poitiers, France, 2Centre d’Investigation Clinique 1402, University Hospital of Poitiers, Poitiers, France, 3University Clinic of Internal Medicine III/Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria, 4Cardiology Department, European Hospital Georges Pompidou, Paris, France, 5Cardiology Department, University Hospital, Dijon, France, 6Division of Geriatric Medicine, Tours University Hospital, Tours, France, 7Heart and Vascular Center, Semmelweis University, Budapest, Hungary, 8School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, Netherlands

Background: The pathophysiology of persistent atrial fibrillation (AF) remains unclear. While several studies have demonstrated an association between myocardial infarction and atrial fibrillation, the role of stable coronary artery disease (CAD) is still unknown. As a result, we aimed to assess the association between CAD obstruction and AF recurrence after persistent AF ablation in patients with no history of CAD.

Materials and methods: This observational retrospective study included consecutive patients who underwent routine preprocedural cardiac computed tomography (CCT) before persistent AF ablation between September 2015 and June 2018 in 5 European University Hospitals. Exclusion criteria were CAD or coronary revascularization previously known or during follow-up. Obstructive CAD was defined as luminal stenosis ≥ 50%.

Results: All in all, 496 patients (mean age 61.8 ± 10.0 years, 76.2% males) were included. CHA2DS2-VASc score was 0 or 1 in 225 (36.3%) patients. Obstructive CAD was present in 86 (17.4%) patients. During the follow-up (24 ± 19 months), 207 (41.7%) patients had AF recurrence. The recurrence rate was not different between patients with and without obstructive CAD (43.0% vs. 41.5%, respectively; P = 0.79). When considering the location of the stenosis, the recurrence rate was higher in the case of left circumflex obstruction: 56% vs. 32% at 2 years (log-rank P ≤ 0.01). After Cox multivariate
Analysis, circumflex artery obstruction (HR 2.32; 95% CI 1.36–3.98; \( P < 0.01 \)) was independently associated with AF recurrence.

**Conclusion:** Circumflex artery obstruction detected with CCT was independently associated with 2-fold increase in the risk of AF recurrence after persistent AF ablation. Further research is necessary to evaluate this pathophysiological relationship.

**KEYWORDS**
atrial fibrillation, ablation, electrophysiology, coronary artery disease, pathophysiology, cardiac computed tomography (CCT), pulmonary vein isolation (PVI)

**Introduction**

The number of atrial fibrillation (AF) ablation procedures is increasing tremendously worldwide (1, 2). While the mechanisms underlying paroxysmal AF are relatively well-understood, the pathophysiology of persistent AF is complex (3), with atrial substrate and fibrosis playing a crucial role in the genesis and perpetuation of the arrhythmia (4). Myocardial infarction is often associated with AF and may be one of its underlying causes (5–7). Several mechanisms regarding this association have been proposed, including heart failure, inflammation, and atrial ischemia (8–11). Nevertheless, the extent to which asymptomatic coronary artery disease (CAD) may impact AF recurrence after ablation has not been adequately investigated. Up until now, only one single-center study, with a small number of patients and short follow-up, has been published, and no association was found between CAD and arrhythmia recurrence (12).

Preprocedural cardiac computed tomography (CCT) is often performed to assess pulmonary vein anatomy, left atrial dimensions, and to exclude left atrial thrombus before AF catheter ablation (13). Moreover, it is possible to assess the presence of coronary artery stenosis (CAS) at the same time. We consequently hypothesized that coronary stenosis on CCT may be predictive of AF ablation success rate.

The purpose of the current study was to investigate the relation between asymptomatic obstructive CAD and AF recurrence after catheter ablation of persistent AF in a large-scale European multicenter cohort.

**Materials and methods**

**Study population**

Consecutive adult patients with symptomatic, drug-refractory persistent AF referred for catheter ablation who underwent preprocedural CCT were screened between September 2015 and June 2018 in 5 European Cardiology Department (the University Hospital of Poitiers, University Hospital of Dijon and European Hospital Georges Pompidou in France, University Hospital of Innsbruck in Austria and Heart and Vascular Center of Semmelweis University in Hungary). Patients with previously known CAD or revascularization during follow-up were excluded. The study was conducted in accordance with the Declaration of Helsinki. All the patients included in this study received an information. According to institutional policy, approval from the Institutional Review Board was not required.

**Cardiac computed tomography**

Cardiac computed tomography was performed routinely 1–4 weeks prior to AF ablation using standard-of-care, site-specific protocols. The complete heart volume was acquired on a high definition CT scanner within one gantry rotation, allowing a good image quality of the coronary arteries (14, 15). CCT analysis was performed by a single reader blinded to the procedural electrophysiology result. According to the previous study published, the severity of CAD was classified in two categories: obstructive (luminal stenosis \( \geq 50\% \)) or non-obstructive (absence of CAD or luminal stenosis < 50%) (16). Localization (right coronary, circumflex, and left anterior descending artery) of the lesion was also specified.

**Atrial fibrillation ablation**

Atrial fibrillation ablation procedures were performed using a cryoballoon ablation catheter (Arctic Front Advance; Medtronic, Inc, Minneapolis, MN, USA) or an open-irrigated radiofrequency ablation catheter (NaviStar, ThermoCool, or ThermoCool SmartTouch; Biosense Webster, Inc, Diamond Bar, CA, USA; Flexability, Tacticath,
### TABLE 1 Baseline characteristics.

|                         | Whole population | AF recurrence N = 207 | No AF recurrence N = 289 | P-value |
|-------------------------|------------------|-----------------------|--------------------------|---------|
| Age, years              | 61.8 ± 10.0      | 62.5 ± 9.5            | 61.4 ± 10.3              | 0.24    |
| Male                    | 378 (76.2)       | 154 (74.4)            | 224 (77.5)               | 0.42    |
| Body mass index, kg/m²  | 29.0 ± 5.2       | 29.3 ± 5.4            | 28.3 ± 5.1               | 0.33    |
| Hypertension            | 323 (65.1)       | 145 (70.0)            | 178 (61.8)               | 0.05    |
| Diabetes                | 69 (13.9)        | 24 (11.6)             | 45 (15.6)                | 0.21    |
| Hypercholesterolemia    | 230 (46.4)       | 89 (43.0)             | 141 (48.8)               | 0.20    |
| CHA²DS²-VASc score      |                  |                       |                          | 0.91    |
| 0–1                     | 225 (36.3)       | 92 (44.4)             | 133 (46.0)               |         |
| 2–3                     | 210 (42.3)       | 90 (43.5)             | 120 (41.5)               |         |
| ≥4                      | 61 (12.3)        | 25 (12.1)             | 36 (12.5)                |         |
| Left ventricular ejection fraction,% | 56.4 ± 11.1 | 55.0 ± 11.0 | 57.4 ± 11.1 | 0.02 |
| Medication              |                  |                       |                          |         |
| NOAC                    | 286 (57.7)       | 114 (55.1)            | 172 (59.5)               | 0.32    |
| Vitamin K antagonist    | 133 (26.8)       | 64 (30.9)             | 69 (23.9)                | 0.08    |
| β-blockers              | 327 (65.9)       | 141 (68.1)            | 186 (64.4)               | 0.38    |
| ACEi                    | 139 (28.0)       | 57 (27.5)             | 82 (28.4)                | 0.84    |
| Antiplatelet agents     | 17 (3.4)         | 10 (4.8)              | 7 (2.4)                  | 0.15    |
| Flecainide              | 34 (6.9)         | 10 (4.8)              | 24 (8.3)                 | 0.13    |
| Amiodarone              | 181 (36.5)       | 75 (36.2)             | 106 (36.7)               | 0.92    |
| AF ablation energy      |                  |                       |                          | 0.05    |
| Radiofrequency          | 431 (86.9)       | 187 (90.3)            | 244 (84.4)               |         |
| Cryoballoon             | 65 (13.1)        | 20 (9.7)              | 45 (15.6)                |         |
| AF ablation lesion set  |                  |                       |                          | 0.18    |
| PVI alone               | 294 (59.3)       | 118 (57.0)            | 176 (60.9)               |         |
| PVI + CFAE              | 70 (14.1)        | 29 (14.0)             | 41 (14.2)                |         |
| PVI + lines             | 114 (23.0)       | 48 (23.2)             | 66 (22.8)                |         |
| PVI + CFAE + lines      | 18 (3.6)         | 12 (5.8)              | 6 (2.1)                  |         |

Results are expressed as mean ± SD or number (%). ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; CFAE, complex fractionated atrial electrograms; PVI, pulmonary vein isolation; NOAC, novel oral anticoagulants.

Tacticath SE Abbott, Mineapolis, MN, USA) using an electroanatomical mapping system (Carto 3 or EnSite Precision). Briefly, all the patients underwent standard pulmonary vein isolation and electrical isolation was confirmed by a circular multipolar electrode mapping catheter. Additional ablation lesions, such as ablation of complex fractionated atrial electrograms, or mitral, roof, and cavotricuspid lines, were performed at the discretion of the operator.

**Endpoints and data collection**

The primary objective was to assess the association between obstructive CAD and AF recurrence after persistent AF ablation. Data were collected using an anonymized spread-sheet-based template. Socio-demographic and clinical characteristics were collected at the time of AF ablation. CHA²DS²-VASc score was calculated at admission (17). Before AF ablation, all the patients underwent standard two-dimensional transthoracic echocardiography to assess left ventricular ejection fraction, calculated according to the recommendations of the American Society of Echocardiography (18).

**Follow-up**

Patients were followed up from the time of AF ablation for at least 1 year. All the hospitalization and consultation reports were examined. If necessary, general practitioners and referring cardiologists were contacted to provide previously missing information. Atrial fibrillation recurrences were assessed after a 3-month blanking period (19, 20), and defined as ≥ 1 AF episode recorded during a 12 lead ECG or ≥ 1 AF episode lasting ≥ 30 s documented by Holter monitoring (21). Most of patients had an ECG at 3 months, and a 24-h Holter monitoring at 6, 12, and 24 months.
TABLE 2 Cardiac computed tomography characteristics.

|                                     | All population | AF recurrence | No AF recurrence | P-value |
|-------------------------------------|----------------|---------------|-----------------|---------|
|                                     | N = 496        | N = 207       | N = 289         |         |
| Left atrial indexed volume, ml/m²²  | 65.4 ± 23.7    | 69.3 ± 26.5   | 62.6 ± 21.1     | <0.01   |
| Obstructive coronary stenosis       | 86 (17.3)      | 37 (17.9)     | 49 (17.0)       | 0.79    |
| Number of obstructed vessels        |                |               |                 | 0.11    |
| 0                                  | 410 (82.7)     | 170 (82.1)    | 240 (83.0)      |         |
| 1                                  | 54 (10.9)      | 18 (8.7)      | 36 (12.5)       |         |
| 2                                  | 24 (4.8)       | 14 (6.8)      | 10 (3.5)        |         |
| 3                                  | 8 (1.6)        | 5 (2.4)       | 3 (1.0)         |         |

Results are expressed as mean ± SD or number (%). AF, atrial fibrillation.

TABLE 3 Multivariable Cox analysis for AF recurrence after persistent AF ablation.

|                                     | Initial model | Final model |
|-------------------------------------|---------------|-------------|
|                                     | Hazard ratio  | 95% CI      | P-value     |
| Age, per 1 year increase            | 1.005         | 0.989–1.022 | 0.53        |
| Body mass index, per 1 kg/m² increase| 1.035         | 1.006–1.065 | 0.02        |
| Hypertension                        | 1.042         | 0.748–1.450 | 0.81        |
| Diabetics                           | 0.795         | 0.508–1.244 | 0.32        |
| β-blockers                          | 1.260         | 0.933–1.701 | 0.13        |
| Amiodarone                          | 0.940         | 0.704–1.255 | 0.67        |
| LVEF, per 1% increase               | 0.996         | 0.985–1.008 | 0.53        |
| LAIV, per 1 ml/m²² increase         | 1.011         | 1.006–1.017 | <0.001      |
| Circumflex artery obstruction       | 2.322         | 1.355–3.978 | <0.01       |
| Ablation technique other than PVI combined (ref PVI only) | 0.899 | 0.674–1.198 | 0.47 |

LAIV, left atrial indexed volume; LVEF, left ventricular ejection fraction; PVI, pulmonary vein isolation.

FIGURE 1
Atrial fibrillation recurrence according to the localization of the obstruction. Arrhythmia recurrences did not differ between obstructed and non-obstructed groups regarding the LAD and the RCA. On the contrary, AF recurrences were higher in patients with circumflex artery obstruction compared to patients without circumflex artery obstruction. Abbreviations: AF, atrial fibrillation; Cx, circumflex artery; LAD, left anterior descending; RCA, right coronary artery.
Garcia et al. 10.3389/fcvm.2022.873135

Statistical analysis

Continuous variables were expressed as mean and SD or median and interquartile range as appropriate, and categorical variables were reported as numbers and percentages. Comparisons between groups were performed using the Student t-tests or the Mann–Whitney U tests for continuous variables as appropriate, and χ² test for categorical variables. Cumulative incidence curves were built according to the presence or absence of circumflex artery obstruction using the Kaplan–Meier method and compared using a log-rank test. For analysis of the predictive value of circumflex artery obstruction, recurrences during the first 3 months after the ablation procedure (blanking period) were not taken into account (20). Multivariate Cox analysis using an entry procedure was performed on an initial model including factors known to be associated with AF recurrence (age, body mass index, hypertension, diabetes, indexed left atrial volume, left ventricular ejection fraction, β-blockers, amiodarone, pulmonary vein isolation alone or with additional lesion set, circumflex artery obstruction). Left anterior descending artery and right coronary artery occlusion were forced into the model in order to see if the association between circumflex artery obstruction and AF recurrence changed. Analyses were performed using SPSS 22 (SPSS, Inc., Chicago, IL, USA) and SAS 9.3 (SAS Institute Inc., Cary, NC, USA) statistical software. Two-sided p-values of less than 0.05 were considered statistically significant.

Results

Baseline characteristics

Among 652 patients who had preprocedural CCT for persistent AF ablation, 156 (23.9%) were not included because of CAD or coronary revascularization, or impossible coronary assessment due to the quality of the exam. Finally, 496 patients were analyzed. Table 1 illustrates the baseline characteristics of the population. Mean age was 61.8 ± 10.0 years, and 378 (76.2%) patients were men. Mean body mass index was 29.0 ± 5.2 kg/m² and 323 (65.1%) had previous hypertension. CHA²DS²–VASc score was of 0 or 1 point in 225 (36.6%) patients and 2 or 3 points in 210 (42.3%) patients. Mean left ventricular ejection fraction was 56.4 ± 11.1% and mean left atrial indexed volume was 65.4 ± 23.7 ml/m². In the terms of medications, 419 (84.4%) patients were prescribed anticoagulant therapy, 327 (65.9%) β-blockers, and 181 (36.5%) amiodarone.

Ablation was performed with radiofrequency ablation catheter in 431 (86.9%) patients and with cryoballoon catheter in 65 (13.1%). Among them, 294 (59.3%) had pulmonary vein isolation alone and 202 (40.7%) underwent additional lesion sets.

Prevalence and characteristics of coronary stenosis

Obstructive CAD was present in 86 (17.3%) patients (Table 2). Obstructive CAD was observed in the left anterior...
Asymptomatic left circumflex artery stenosis is associated with higher arrhythmia recurrence after persistent AF ablation

Aim
To assess the association between CAD obstruction and AF recurrence after persistent AF ablation in patients with no history of CAD

Results
• 496 patients included (age 62 years, 76% males)
• 17.4% with asymptomatic coronary artery obstruction
• Circumflex artery occlusion associated with 2-fold higher probability of AF recurrence

Central illustration. In total, 496 patients had CCT before persistent AF ablation. Among them 17.4% had coronary obstruction. Circumflex artery occlusion was associated with a 2-fold higher probability of AF recurrence during follow-up. Abbreviations: AF, atrial fibrillation; CCT, cardiac computed tomography.

FIGURE 3

Recurrence of atrial fibrillation and coronary artery stenosis status

During the mean follow-up of 24 ± 19 months, AF recurrence occurred in 207 (41.7%) patients. AF recurrence rate was not different when considering the number of obstructed coronary arteries: 42.9% in the non-lesion group, 41.1% in the single-vessel lesion group, 41.1% in the 2-vessel lesion group, and 40.8% in the 3-vessel lesion group (P = 0.98).

In addition, AF recurrence rate did not differ between patients according to the presence of obstructive CAD [absence of obstructive CAD: 170 (41.5%) patients; obstructive CAD: 37 (43.0%) patients; P = 0.79]. When considering the location of the obstruction there was no difference in relation to outcome seen between those with vs. without obstruction in the left anterior descending and right coronary arteries. On the other hand, the recurrence rate was significantly higher in case of circumflex artery obstruction (Figure 1). The Kaplan–Meier analysis confirmed a higher risk of AF recurrence in the group in which circumflex artery was stenosed. At 1 year, documented recurrence of AF had occurred in 48.0% (12 out of 25) of patients with circumflex artery obstruction and in 26.1% (123 of the 471) of patients without circumflex artery obstruction. At 2 years, documented recurrence of AF had occurred in 56.0% (14 of the 25) of patients with circumflex artery obstruction and in 32.1% (151 of the 471) of patients without circumflex artery obstruction (Log-rank hazard ratio [HR], 2.06; 95% confidence interval [CI], 1.02 to 4.16; P < 0.01) (Figure 2). Baseline characteristics of the patients according to circumflex artery obstruction are given in Supplementary file 1.

Multivariable Cox regression analysis showed that body mass index (HR 1.04; 95% CI 1.01–1.07 per 1 kg/m^2 increase; P = 0.02), left atrial indexed volume (HR 1.01; 95% CI 1.01–1.02 per 1 ml/m^2 increase; P < 0.001), and circumflex artery obstruction (HR 2.32; 95% CI 1.36–3.98; P < 0.01) were independently associated with AF recurrences at follow-up after persistent AF ablation (Table 3). When left anterior descending artery and right coronary artery occlusion were forced in the model, those two variables were not associated with AF recurrence and circumflex artery obstruction was still associated with AF recurrences (HR 2.45; 95% CI 1.37–4.36; P < 0.01).

Discussion

In this large-scale international study bringing together 496 patients referred for persistent AF ablation, 5% had obstructive
CAD located on the circumflex artery determined by CCT before ablation (Figure 3). This parameter was independently associated with a doubled risk of AF recurrence after ablation, along with of left atrial indexed volume and body mass index.

Prevalence of asymptomatic coronary artery stenosis before atrial fibrillation ablation

Previous studies found prevalence of asymptomatic obstructive CAD ranging from 24 to 41% (16, 22), which was substantially higher than the proportion in our study (17.3%). This difference might be explained by the lower prevalence of cardiovascular risk factors and above all by the higher prevalence of women in our study compared to the one authored by Nucifora et al. Mito’s work had also an older population compared to ours.

Association between coronary artery stenosis and atrial fibrillation recurrence

This is the first multicenter study assessing the impact of coronary artery stenosis on AF recurrence after persistent AF ablation. Coronary artery disease might be responsible for AF with several mechanisms: chronic inflammation, heart failure causing atrial stretch, and finally ischemia, all of which are responsible for fibrosis (4, 23–25). In our study, AF recurrence was not significantly different between patients with obstructive CAD and patients without obstructive CAD. These results are in line with a previous study carried out on a limited number of patients with shorter follow-up (12). In order to explore a possible effect of the CAD localization, Kornej et al. tried to determine whether a right coronary stenosis was associated with outcomes after AF ablation but the recurrence rate did not depend on obstruction (26). The present work is the first to evaluate the role of each coronary artery.

Role of circumflex artery in atrial fibrillation recurrences

The anatomy of coronary arteries supplying the left atrium has been described as originating from the first segment of the circumflex artery (27, 28), and Alasady et al. demonstrated that the involvement of the left atrial coronary branch during myocardial infarction was associated with AF onset (29). Moreover, a study on experimental myocardial infarction on swine demonstrated that proximal circumflex artery occlusion involving the left atrial branch was associated with atrial infarction and atrial structural remodeling, characterized by early left atrial dilation, dysfunction, and fibrosis. When proximal circumflex artery occlusion was performed in swine without involving the left atrial branch, only interstitial atrial fibrosis was found with a lesser degree of left atrial dilation or dysfunction, and in cases of left anterior descending occlusion, no atrial fibrosis was found, and there was no left atrial remodeling (24). Taken together, these studies highlight the involvement of the circumflex artery in left atrial vascularization and suggest atrial ischemia and infarction as potential mechanisms of atrial fibrosis and AF. In the present work, only circumflex stenosis, without known clinical infarction, was associated with a higher rate of AF recurrence. These results argue for a regional and targeted, not just global (30), pathophysiological mechanism of atherosclerosis on the perpetuation of atrial fibrillation (31). The other consequence of these findings is that not only symptomatic myocardial infarction, but also silent CAD, is associated with AF recurrence. The mechanism leading to AF recurrence could consequently be silent chronic atrial ischemia related to circumflex coronary stenosis. To shed further light on these results, atrial substrate evaluation through electroanatomical mapping and cardiac magnetic resonance imaging combined with detailed coronary angiography could add new data on the role of the circumflex artery and ischemia in atrial fibrillation.

Limitations

The absence of uniformity in CCT protocols is a methodological limitation. Nevertheless, we were able to highlight the role of circumflex artery stenosis in AF recurrence, which strengthens this result on account of the assessment heterogeneity. Second, the latest classification of coronary artery disease (CAD RAD) was not used in our study because it was not available on all CCT reports (32). However, we have chosen a cutoff (50%) that has already been used in the literature and which reflects a significant rate of CAD (16). In addition, the small number of patients with circumflex artery stenosis (25 patients with LCX obstruction vs. 471 patients without LCX) may have a significant impact on the statistics. Minor change in number recurrence might come to statistic difference. Finally, given the limited CT scan resolution for small artery assessment, we were not able to assess lesions located on the atrial branch of the circumflex artery.

Conclusion

In a large population of patients undergoing persistent AF catheter ablation, this study demonstrates that obstructive stenosis of the circumflex artery defined by pre-procedural
CT scan is independently associated with AF recurrence. Further studies are required to investigate the pathophysiology associated with this finding.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

All patients included in this study received an information letter. According to institutional policy, approval from Institutional Review Board was not required. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication.

Acknowledgments

We thank Jeffrey Arsham for rereading assistance.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.873135/full#supplementary-material

References

1. Calkins H, Hindricks G, Cappato R, Kim Y-H, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. (2017) 14:e273–444.
2. Gandjbakhch, E, Mandel F, Dagher Y, Hidden-Luetz F, Rollin A, Maury P. Incidence, epidemiology, diagnosis and prognosis of atrio-oesophageal fistula following percutaneous catheter ablation: a French nationwide study. Europace. (2020) 23:557–564. doi: 10.1093/europace/euaa278
3. Lee S, Khrestian CM, Sahadevan J, Markowitz A, Waldo AL. New insights into understanding rotor versus focal activation in patients with persistent atrial fibrillation. JACC Clin Electrophysiol. (2021) 7:909–19. doi: 10.1016/j.jacep.2020.12.010
4. Marrouche NF, Wilber D, Hindricks G, Iais P, Akoum N, Marchlinski F, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA. (2014) 311:498–506.
5. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. (2009) 30:1038–45.
6. Guenancia C, Tousca C, Fauchier L, Stamboul K, Garnier F, Mouhat B, et al. High rate of recurrence at long-term follow-up after new-onset atrial fibrillation during acute myocardial infarction. Europace. (2018) 20:e179–88.
7. Hiraya D, Sato A, Hoshi T, Watabe H, Yoshida K, Komatsu Y, et al. Impact of coronary artery disease and revascularization on recurrence of atrial fibrillation after catheter ablation: importance of ischemia in managing atrial fibrillation. J Cardiovasc Electrophysiol. (2019) 30:1491–8. doi: 10.1111/jce.14029
8. Yu-ki, Kunihiro N, Takeshi K, Stanley N. Atrial fibrillation pathophysiology. Circulation. (2011) 124:2264–74.
9. Jason A, Paul K, Dobromir D, Stanley N. The clinical profile and pathophysiology of atrial fibrillation. Circ Res. (2014) 114:1453–68.
10. Raphael CE, Hett JA, Reeder GS, Bois MC, Malezewski JI, Tilbury RT, et al. Coronary embolus: an underappreciated cause of acute coronary syndromes. JACC Cardiovasc Interv. (2018) 11:172–80.
11. Hani S, Katayoun D, Danielle L, Yahye M, Ki I, Tack, Stanley N. Atrial ischemia promotes atrial fibrillation in dogs. Circulation. (2003) 107:1930–6.
12. den Uijl DW, Roogers MJ, Compier M, Trines SA, Scholte AJHA, Zeppenfeld K, et al. Impact of coronary atherosclerosis on the efficacy of radiofrequency catheter ablation for atrial fibrillation. Eur Heart J Cardiovasc Imaging. (2013) 14:247–52.
13. Link Mark S, Michel H, Andrea N. Ablation of atrial fibrillation. Circulation. (2016) 134:339–52.
14. Andreini D, Pontone G, Mushtaq S, Conte E, Perichinumino M, Guglielmo M, et al. Atrial fibrillation: diagnostic accuracy of coronary CT angiography performed with a whole-heart 230-µm spatial resolution CT scanner. Radiology. (2017) 284:676–84. doi: 10.1148/radiol.2017161779
15. Xu L, Yang L, Fan Z, Yu W, Lv B, Zhang Z. Diagnostic performance of 320-detector CT coronary angiography in patients with atrial fibrillation: preliminary results. Eur Radiol. (2011) 21:936–43. doi: 10.1007/s00330-010-1987-0.
16. Nucifora G, Schuijf JD, Tops LE, van Werkhoven JM, Kajander S, Jukema JW, et al. Prevalence of coronary artery disease assessed by multislice computed tomography coronary angiography in patients with paroxysmal or persistent atrial fibrillation. Circ Cardiovasc Imaging. (2009) 2:100–6.
17. Lip GVH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. (2010) 137:263–72. doi: 10.1378/chest.09-1584
18. Gottlieb JS, Bednarz J, Devereux R, Gardin J, Klehn A, Manning WL, et al. American society of echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr. (2004) 17:1086–119.
19. Mansour M, Calkins H, Ossorio J, Pollak SJ, Melby D, Marchlinski FE, et al. Persistent atrial fibrillation ablation with contact force-sensing catheter: the prospective multicenter PRECEPT trial. JACC Clin Electrophysiol. (2020) 6:958–69. doi: 10.1016/j.jacep.2020.04.024
20. Aryana A, Allen SL, Pujara DK, Bowens MR, O’Neill PG, Yamauchi Y, et al. Concomitant pulmonary vein and posterior wall isolation using cryoballoon with adjunct radiofrequency in persistent atrial fibrillation. JACC Clin Electrophysiol. (2021) 7:187–96.
21. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association of cardio-thoracic surgery (EACTS). Eur Heart J. (2020) 42:373–498. doi: 10.1093/eurheartj/ehaa612
22. Mito T, Takemoto M, Antoku Y, Masumoto A, Nozoe M, Kinoshita S, et al. Evaluation of coronary artery disease in patients with atrial fibrillation by cardiac computed tomography for catheter ablation: CADAF-CT trial. Heart Vessels. (2020) 35:1037–43.
23. De Jong AM, Maass AH, Oberdorf-Maass SJ, Van Veldhuisen DJ, Van Gilst WH, Van Gelder IC. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. Cardiovasc Res. (2011) 89:754–65.
24. Aguero J, Galan-Arriola C, Fernandez-Jimenez R, Sanchez-Gonzalez J, Ajmone N, Delgado V, et al. Atrial infarction and ischemic mitral regurgitation contribute to post-MI remodeling of the left atrium. J Am Coll Cardiol. (2017) 70:2878–89. doi: 10.1016/j.jacc.2017.10.013
25. Li X, Garcia-Elias A, Benito B, Nattel S. The effects of cardiac stretch on atrial fibroblasts: analysis of the evidence and potential role in atrial fibrillation. Cardiovasc Res. (2022) 108:440–460. doi: 10.1093/cvr/cvab035
26. Kornej J, Hindricks G, Arya A, Sommer P, Husser D, Rolf S, et al. Presence and extent of coronary artery disease as predictor for AF recurrences after catheter ablation: the Leipzig heart center AF-ablation registry. Int J Cardiol. (2015) 181:188–92. doi: 10.1016/j.ijcard.2014.12.039
27. James TN, Burch GE. The atrial coronary arteries in man. Circulation. (1958) 17:90–8.
28. Alasady M, Abhayaratna WP, Leong DP, Lim HS, Ahe HS, Brooks AG, et al. Atrial coronary arteries in areas involved in atrial fibrillation catheter ablation. Circ Arrhythm Electrophysiol. (2010) 3:600–5.
29. Amador D, Aguirre J, Galan-Arriola C, Fernandez-Jimenez R, Sanchez-Gonzalez J, Ajmone N, Delgado V, et al. Clinically important modulation of the atrial coronary arteries in areas involved in atrial fibrillation catheter ablation. J Am Coll Cardiol. (2017) 70:2878–89. doi: 10.1016/j.jacc.2017.10.013
30. Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Rooij FIA, Lip GYH, et al. Subclinical atherosclerosis and risk of atrial fibrillation: the rotterdam study. Arch Intern Med. (2007) 167:382–7.
31. Aguilar M, Rose RA, Takawale A, Nattel S, Reilly SB. New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation. Cardiovasc Res. (2021) 117:1645–61. doi: 10.1093/cvr/cvab080
32. Cury RC, Abbara S, Achenbach S, Agatston A, Berman DS, Budoff MJ, et al. CAD-RADSTM: coronary artery disease - reporting and data system: an expert consensus document of the society of cardiovascular computed tomography (SCCT), the American college of radiology (ACR) and the North American society for cardiovascular imaging (NASCI). Endorsed by the American college of cardiology. J Am Coll Radiol. (2016) 13:1458.e–66.e.